Results 121 to 130 of about 34,135 (204)

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

International Journal of Cancer, Volume 158, Issue 6, Page 1675-1689, 15 March 2026.
What's new? CATCH is a prospective precision oncology registry trial that harnesses whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer patients of any subtype. The data of the first 412 consecutive patients with completed follow‐up in this real‐world, single‐center patient cohort provide robust ...
Mario Hlevnjak, Sabine Heublein, Verena Thewes, Lukas Wagener, Constantin Pixberg, Carlo Fremd, Laura Michel, Christian Maurer, Lars Buschhorn, Nicola Dikow, Fangyoumin Feng, Stefan Fröhling, Christel Herold‐Mende, Steffen Hirsch, Chen Hong, Daniel Hübschmann, Lena Jassowicz, Polina Kozyulina, Katrin Pfütze, Richard F. Schlenk, Hans‐Peter Sinn, Katharina Smetanay, Christoph Springfeld, Albrecht Stenzinger, Celina Wagner, Stephan Wolf, Andreas Trumpp, Dirk Jäger, Oliver Zivanovic, Marc Zapatka, Andreas Schneeweiss, Peter Lichter   +31 more
wiley   +1 more source

SPHK1 enhances olaparib resistance in ovarian cancer through the NFκB/NRF2/ferroptosis pathway

Cell Death Discovery
PARPis resistance is a challenge in the treatment of ovarian cancer. To investigate the potential mechanism involved in olaparib resistance of ovarian cancer, high-throughput sequencing was performed on olaparib-resistant SKOV3 cell line named SK/Ola ...
Kai Teng, Hanlin Ma, Panpan Gai, Xuelian Zhao, Gonghua Qi   +4 more
doaj   +1 more source

Mechanisms of nuclear content loading to exosomes. [PDF]

, 2019
Exosome cargoes are highly varied and include proteins, small RNAs, and genomic DNA (gDNA). The presence of gDNA suggests that different intracellular compartments contribute to exosome loading, resulting in distinct exosome subpopulations.
Burks, Jared K, Clise-Dwyer, Karen, De Hoff, Peter, Laurent, Louise C, Liu, Jinsong, Morey, Robert, O'Halloran, Theresa J, Oliphint, Paul Allen, Roszik, Jason, Song, Xingzhi, Sood, Anil K, Villar-Prados, Alejandro, Yokoi, Akira, Zhang, Jianhua   +13 more
core  

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions [PDF]

, 2016
Poly(ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombination (HR)-deficient cancers, including BRCA-mutated tumours, by exploiting synthetic lethality.
Konecny, G, Kristeleit, RS
core  

Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1‐2 Pathogenic Variants

Cancer Medicine
Introduction Pancreatic cancer arising in the context of BRCA predisposition may benefit from poly(ADP‐ribose) polymerase inhibitors. We analyzed real‐world data on the impact of olaparib on survival in metastatic pancreatic cancer patients harboring ...
Michele Milella, Giulia Orsi, Mariacristina diMarco, Lisa Salvatore, Letizia Procaccio, Silvia Noventa, Silvia Bozzarelli, Ingrid Garajova, Enrico Vasile, Guido Giordano, Marina Macchini, Alessandro Cavaliere, Marina Gaule, Francesca Bergamo, Marta Chiaravalli, Andrea Palloni, Riccardo Carloni, Alessandro Bittoni, Monica Niger, Ilario Giovanni Rapposelli, Maria Grazia Rodriquenz, Mario Scartozzi, Stefania Mosconi, Elisa Giommoni, Ilaria Bernardini, Chiara Paratore, Andrea Spallanzani, Katia Bencardino, Laura Forti, Emiliano Tamburini, Sara Lonardi, Aldo Scarpa, Stefano Cascinu, Giampaolo Tortora, Isabella Sperduti, Michele Reni   +35 more
doaj   +1 more source

Pulmonary Embolism Associated with Olaparib in BRCA2-Mutated Prostate Cancer: A Case Report

Current Oncology
Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor approved for treating metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations, has significant clinical benefits.
Shuhei Ishii, Shigekatsu Maekawa, Fumiko Amano, Daichi Kikuchi, Daiki Ikarashi, Renpei Kato, Mitsugu Kanehira, Ryo Takata, Jun Sugimura, Wataru Obara   +9 more
doaj   +1 more source

Targeted Therapies for Ovarian Cancer [PDF]

, 2016
Epithelial ovarian cancer has the highest mortality rate of all gynaecological malignancies. Most women present with advanced disease and develop a recurrence after radical surgery and chemotherapy.
Grunewald, T, Ledermann, JA
core  

Carcinoma de ovario recurrente y platino sensible. A propósito de un caso clínico. [PDF]

, 2017
El cáncer de ovario es la cuarta causa de muerte por cáncer en la mujer. Esta enfermedad es, hoy día, una neoplasia que interfiere sumamente en la vida de las pacientes. Se presenta el caso de una paciente de 37 años que recibió múltiples tratamientos
Benítez Reguera, Mercedes
core  

Olaparib enhancing radiosensitization and anti-metastatic effect of oral cancer by targeting IL-17A signal

Cancer Cell International
Purpose We tested whether the PARP inhibitor, Olaparib, can effectively enhance radiosensitivity while inhibiting OSCC growth and metastasis in vitro and in vivo. Patient samples were used for survival validation.
Chih-Chia Yu, Hon-Yi Lin, Michael W.Y. Chan, Shu-Fen Wu, Wen-Yen Chiou, Moon-Sing Lee, Chen-Lin Chi, Ru-Inn Lin, Feng-Chun Hsu, Hsuan-Ju Yang, Liang-Cheng Chen, Chia-Hui Chew, Shih-Kai Hung   +12 more
doaj   +1 more source

Clinical Impact of Olaparib for Platinum-Sensitive Recurrent Ovarian Cancer

Diseases
Background/Objectives: Olaparib, a poly ADP ribose polymerase inhibitor, has been effective in prolonging progression-free survival in platinum-sensitive recurrent ovarian cancer.
Hiroaki Ishida, Megumi Manrai, Akiko Takashima, Hiroki Egashira, Mizuki Nonaka, Hideaki Shimada   +5 more
doaj   +1 more source